Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U) |
| |
Authors: | Jun-ichi Kitagawa Takeshi Hara Hisashi Tsurumi Naoe Goto Nobuhiro Kanemura Takeshi Yoshikawa Senji Kasahara Toshiki Yamada Michio Sawada Takeshi Takahashi Masahito Shimizu Tsuyoshi Takami Hisataka Moriwaki |
| |
Institution: | (1) First Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan;(2) Division of Hematology, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu 500-8513, Japan;(3) Department of Immunopathology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan |
| |
Abstract: | Purpose The aim of this study was to assess the prognostic factors of peripheral T-cell lymphoma, unspecified (PTCL-U).
Patients and methods We retrospectively analyzed 30 cases fulfilling the criteria of PTCL-U defined by the World Health Organization classification.
The patients were treated with 6–8 cycles of a CHOP or THP (pirarubicin)-COP regimen.
Results A high serum sIL-2R level (≥2,000 U/ml) at onset was associated with a low complete remission rate. Patients with high sIL-2R
had significantly lower survival rates (5 year, 15.1%) than those with low sIL-2R (<2,000 U/ml) (100%) (P < 0.005). Factors associated with worse overall survival in a univariate analysis were high sIL-2R (P < 0.005), high age (>60 years) (P < 0.05), poor performance status (P < 0.01) and poor international prognostic index (P < 0.05). No correlation was observed between sIL-2R and other markers. Multivariate analysis showed that only sIL-2R was
a prognostic factor for overall survival (P < 0.01).
Conclusion The results suggest that a high serum sIL-2R level predicts a poor prognosis in PTCL-U. |
| |
Keywords: | Peripheral T-cell lymphoma (PTCL) Soluble interleukin-2 receptor (sIL-2R) Prognostic analysis |
本文献已被 PubMed SpringerLink 等数据库收录! |
|